Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients

Representative GC chromatogram of serum total and free fatty acids of HBV patients and controls along with standards of fatty acid methyl esters.(DOCX 761 kb

Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B

Abstract Background Hepatitis B virus (HBV) exerts an intense impact on host lipid metabolism. Hence the aim of present study is to determine metabolic derangement that occurred in subjects suffering from hepatitis B patients. Methods The fasting blood samples were collected from hepatitis B patients (n = 50) attended in Taluka hospital TandoAdam, Sindh with age and gender matched controls (n = 50). Serum lipid profile and fatty acid (FA) composition were analyzed by micro-lab and gas chromatography. Results The hepatitis B patients have significantly lower level (p < 0.01) of lipid profile including total cholesterol (TC), triacylglyceride (TAG), high density lipoprotein-C (HDL-C) very low density lipoprotein-cholesterol (VLDL-C), low density lipoprotein-cholesterol (LDL-C), and total lipid (TL) in comparison to controls, indicating hypolipidemia in patients. The result of total FA composition of HBV patients in comparison to controls reveal that myristic, palmitic, docosahexaenoic acids were significantly (p < 0.05) higher, while linoleic, eicosatrienoic, arachidonic, eicosapentaenoic acids were lower in HBV patients in comparison to controls. The elongase, ∆5 and ∆6-desaturase enzymes activities were found lower, while ∆9-desaturase activity was higher in hepatitis B patients as compared to controls, which indicates the impaired lipid metabolism. Conclusion The serum saturated fatty acid (SFA) and monounsaturated fatty acid (MUFA) were increased while polyunsaturated fatty acid (PUFA) was reduced in both total and free form in hepatitis B patients due to altered activities of enzyme desaturases with impaired PUFA metabolism and non-enzymatic oxidation

Comparison between S-Allyl Cysteine and Gliclazide in Lowering the Blood Glucose Levels in Diabetic Rats

BACKGROUND: Diabetes Mellitus is a global problem caused by the deficiency of Insulin secretion either absolute or relative. Treatment options are Insulin and oral glucose lowering drugs. Current study was designed to find out the glucose lowering properties of S-allylcysteine a garlic derivative sulfur containing amino acid. OBJECTIVE: To compare blood glucose lowering effects of S-allylcysteine with gliclazide in diabetic rat model. STUDY DESIGN, PLACE AND DURATION: This 3 months animal study was carried out in animal house of ISRA University Hyderabad from August 2014 to Oct 2014. MATERIAL AND METHODS: 32 Male Wistar Rats were randomly divided into 4 equal groups A, B, C and D after selection through non-probability purposive sampling. Group A and B served as positive and negative controls respectively. Diabetes was induced in Group B, C and D by injecting alloxan at the dose of 120 mg/kg according to the weight of rats. Rats in group C and D were treated with S-allylcysteine (150 mg/kg), gliclazide (5 mg/kg) respectively. Random blood sugar levels of all groups were measured after weeks 1, 2 & 3. The data was analyzed by SPSS version 21.0. RESULTS: Blood glucose levels after 2nd and 3rd week were 264.3 ± 43.16 vs. 218.75 ± 36.38 (p=0.0001) for SAC and 229.0 ± 89.87 vs. 241.0 ± 48.19 mg/dl for Gliclazide (p=0.001) while at the end of 3rd week results for two control groups were non-significant statistically (p-0.07 and0.09). CONCLUSION: It is concluded that S-allylcysteine possess blood glucose lowering properties that are comparable to gliclazide